Crossmark

Response to commentary on “pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors”

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2025.100713

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Barcellos, Marcio https://orcid.org/0009-0009-1547-6689
Braga, Antonio https://orcid.org/0000-0002-2942-6182
Rech, Matheus Machado https://orcid.org/0000-0002-2961-9443
de Oliveira, Solange Artimos https://orcid.org/0000-0002-1862-2348
Madi, Jose Mauro https://orcid.org/0000-0002-2345-4713
Sun, Sue Yazaki https://orcid.org/0000-0001-6573-7386
de Rezende-Filho, Jorge https://orcid.org/0000-0002-2193-3374
Elias, Kevin M. https://orcid.org/0000-0003-1502-5553
Horowitz, Neil S. https://orcid.org/0000-0002-4854-0642
Berkowitz, Ross S. https://orcid.org/0000-0002-7569-898X
Funding

Funding for this research was provided by:

Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-06-10
More Information

This article is maintained by: Elsevier

Article Title: Response to commentary on “pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors”

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2025.100713

Content Type: simple-article

Copyright: © 2025 HCFMUSP. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below